ArticleActa ophthalmologica2025
Choroidal melanoma patient views on the importance of treatment characteristics and outcomes, and physicians' information provision in the Netherlands.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo identify the treatment characteristics and outcomes that Dutch patients with large or juxtapapillary choroidal melanoma consider important when choosing between enucleation and proton beam therapy (PBT). We further determined to what extent these treatment characteristics and outcomes are discussed with newly diagnosed choroidal melanoma patients.
methodsThrough a literature search, stakeholder interviews and feedback from patients, we identified 15 treatment characteristics and outcomes that patients might consider important for deciding between enucleation and PBT. Using a ranking survey, we selected the seven most important characteristics. Next, we conducted a Swing Weighting (SW) survey among treated and newly diagnosed large or juxtapapillary choroidal melanoma patients to determine the relative weight patients assign to these characteristics for treatment decision-making. Furthermore, we assessed which characteristics and outcomes are discussed in current practice with newly diagnosed choroidal melanoma patients eligible for both enucleation and PBT using audio recordings of consultations.
resultsOne hundred sixty-five participants completed the SW survey. The patients found the risk of tumour recurrence and eye loss most important. These were mentioned in 47% and 42% of the 110 audio-recorded consultations, respectively. The two most-often mentioned characteristics were treatment course (96%) and decrease in visual acuity (85%).
conclusionTumour local control and eye preservation matter the most to newly diagnosed choroidal melanoma patients when facing a treatment decision. However, ocular oncologists do not routinely provide this information to patients. The results can be used to align counselling of newly diagnosed patients with choroidal melanoma with what matters most to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.